A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sponsored by IMMUNOVANT
The IMVT-1401-2401 study wants to learn more about the safety and effectiveness of an investigational drug called batoclimab to see if it could help CIDP patients manage their symptoms. Batoclimab is given by a simple injection under the skin that can be given at home in a few seconds and has not been approved by any regulatory health agency for the treatment of CIDP. It is only available to people with autoimmune diseases like CIDP who participate in research studies like this one.
The results of this study will help doctors and researchers better understand how batoclimab may affect symptoms such as muscle weakness, and the ability to perform daily activities, which could improve the quality of life for CIDP patients.
Learn more about the IMVT1401-2401 research study of an injectable investigational drug for adults diagnosed with (CIDP) here www.ResearchCIDP.com